Company: TYRA
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0000950170-25-046124
Chunk: 264

Company: Tyra Biosciences, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 9B
Chunk 264
---
Director and Officer Trading Arrangements:

Rule 10b5-1 Trading PlansFrom time to time, our officers (as defined in Rule 16a-1(f) of the Exchange Act) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the three months ended December 31, 2024, certain of our officers adopted such trading arrangements as noted below: 

      Trading Arrangement

      Name and Title
       
      Action
       
      Date
       
      Rule 10b5-1*
       
      Non-Rule 10b5-1**
       
      Total Shares Authorized to be Sold***

      Expiration Date

      Todd HarrisPresident, Chief Executive Officer and Director
       
       Adoption
       
      11/4/2024
       
      X

      315,000

      12/31/2026

      Daniel BensenChief Operating Officer
       
       Adoption
       
      11/5/2024
       
      X

      350,000

      2/26/2027

      Alan FuhrmanChief Financial Officer
       
       Adoption
       
      11/5/2024
       
      X

      80,000

      7/31/2026
     
     * Intended to satisfy the affirmative defense of Rule 10b5-1(c) ** Not intended to satisfy the affirmative defense of Rule 10b5-1(c) *** Represents the maximum number of shares that may be sold pursuant to the 10b5-1 arrangement. The number of  shares sold is dependent on the satisfaction of certain conditions as set forth in the written plan and the satisfaction of applicable vesting conditions of equity awards.